Genetic variations in vascular endothelial growth factor and endothelial nitric oxide synthase and their contributions to human disease

Microcirculation

Volumn 12, Issue 1, 2005, Pages 129-140

  Gerritsen, Mary E ^a  

^a EXELIXIS INC   (United States)

Author keywords

Atherosclerosis; Genomics; Hypertension; Psoriasis; Vascular disease

Indexed keywords

NITRIC OXIDE SYNTHASE; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D;

AMYOTROPHIC LATERAL SCLEROSIS; ANGIOGENESIS; CANCER RISK; CORONARY ARTERY DISEASE; CORONARY ARTERY SPASM; DIABETIC NEPHROPATHY; DIGEORGE SYNDROME; GENE FREQUENCY; GENE OVEREXPRESSION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEART INFARCTION; HUMAN; HYPERTENSION; MOLECULAR DYNAMICS; NONHUMAN; PATHOPHYSIOLOGY; PLACENTA DISORDER; PRIORITY JOURNAL; PSORIASIS; REVIEW; SMOKING;

CARDIOVASCULAR DISEASES; HUMANS; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; VARIATION (GENETICS); VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 16244370748     PISSN: 10739688     EISSN: None     Source Type: Journal    
DOI: 10.1080/10739680590896081     Document Type: Review

References (65)

1. Abe M, Sato Y. (2001). cDNA microarray analysis of the gene expression profile of VEGF-activated human umbilical vein endothelial cells. Angiogenesis 4:289-298.
2. Albrecht EW, Stegeman CA, Heeringa P, Henning RH, van Goor H. (2003). Protective role of endothelial nitric oxide synthase. J Pathol 199:8-17.
3. Alderton WK, Cooper CE, Knowles RG. (2001). Nitric oxide synthases: structure, function and inhibition. Biochem J 357:593-615.
4. Awata T, Inoue K, Kurihara S, Ohkubo T, Watanabe M, Inukai K, Inoue I, Katayama S. (2002). A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 51:1635-1639.
5. Bates DO, Cui TG, Doughty JM, Winkler M, Sugiono M, Shields JD, Peat D, Gillatt D, Harper SJ. (2002). VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res 62:4123-4131.
6. Bhushan M, McLaughlin B, Weiss JB, Griffiths CE. (1999). Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol 141:1054-1060.
7. Braverman IM, Sibley J. (1982). Role of the microcirculation in the treatment and pathogenesis of psoriasis. J Invest Dermatol 78:12-17.
8. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, Nagy A. (1996). Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380:435-439.
9. Carmeliet P, Lambrechts D, Storkebaum E, Morimoto M, Del-Favero J, Desmet F, Marklund SL, Wyns S, Thijs V, Andersson J, van Marion I, Al-Chalabi A, Bornes S, Musson R, Hansen V, Beckman L, Adolfsson R, Pall HS, Prats H, Vermeire S, Rutgeerts P, Katayama S, Awata T, Leigh N, Lang-Lazdunski L, Dewerchin M, Shaw C, Moons L, Vlietinck R, Morrison KE, Robberecht W, Van Broeckhoven C, Collen D, Andersen PM, Stalmans I, De Smet F, Jansen S, Wang J, Maity S, Kneer P, von der Ohe M, Swillen A, Maes C, Gewillig M, Molin DG, Hellings P, Boetel T, Haardt M, Compernolle V, Plaisance S, Emanuel B, Gittenberger-de Groot AC, Scambler P, Morrow B, Driscol DA, Esguerra CV, Carmeliet G, Behn-Krappa A, Devriendt K, Conway SJ. (2003). Blood vessels and nerves: common signals, pathways and diseases VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death VEGF: a modifier of the del22q11 (DiGeorge) syndrome? Nat Rev Genet 4:710-720.
10. Chang K, Baek SH, Seung KB, Kim PJ, Ihm SH, Chae JS, Kim JH, Hong SJ, Choi KB. (2003). The Glu298Asp polymorphism in the endothelial nitric oxide synthase gene is strongly associated with coronary spasm. Coron Artery Dis 14:293-299.
11. Christinger HW, Muller YA, Berleau LT, Keyt BA, Cunningham BC, Ferrara N, de Vos AM. (1996). Crystallization of the receptor binding domain of vascular endothelial growth factor. Proteins 26:353-357.
12. Cook S, Hugli O, Egli M, Vollenweider P, Burcelin R, Nicod P, Thorens B, Scherrer U. (2003). Clustering of cardiovascular risk factors mimicking the human metabolic syndrome X in eNOS null mice. Swiss Med Wkly 133:360-363.
13. Creamer D, Allen M, Jaggar R, Stevens R, Bicknell R, Barker J. (2002). Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor. Arch Dermatol 138:791-796.
14. Detmar M, Brown LF, Claffey KP, Yeo KT, Kocher O, Jackman RW, Berse B, Dvorak HF. (1994). Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 180:1141-1146.
15. Dor Y, Djonov V, Abramovitch R, Itin A, Fishman GI, Carmeliet P, Goelman G, Keshet E. (2002). Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J 21:1939-1947.
16. Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber HP, Kikkawa Y, Miner JH, Quaggin SE. (2003). Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 111:707-716.
17. Ferrara N. (2002). Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 29:10-14.
18. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell-Braxton L, Hillan KJ, Moore MW. (1996). Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380:439-442.
19. Ferrara N, Gerber HP, LeCouter J. (2003). The biology of VEGF its receptors. Nat Med 9:669-676.
20. Furchgott RF, Zawadzki JV. (1980). The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288:373-376.
21. Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z, Ferrara N. (1999). VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 5:623-628.
22. Giordano FJ, Gerber HP, Williams SP, VanBruggen N, Bunting S, Ruiz-Lozano P, Gu Y, Nath AK, Huang Y, Hickey R, Dalton N, Peterson KL, Ross J Jr, Chien KR, Ferrara N. (2001). A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc Natl Acad Sci U S A 98:5780-5785.
23. Granath B, Taylor RR, van Bockxmeer FM, Mamotte CD. (2001). Lack of evidence for association between endothelial nitric oxide synthase gene polymorphisms and coronary artery disease in the Australian Caucasian population. J Cardiovasc Risk 8:235-241.
24. Hibi K, Ishigami T, Tamura K, Mizushima S, Nyui N, Fujita T, Ochiai H, Kosuge M, Watanabe Y, Yoshii Y, Kihara M, Kimura K, Ishii M, Umemura S. (1998). Endothelial nitric oxide synthase gene polymorphism and acute myocardial infarction. Hypertension 32:521-526.
25. Huez I, Bornes S, Bresson D, Creancier L, Prats H. (2001). New vascular endothelial growth factor isoform generated by internal ribosome entry site-driven CUG translation initiation. Mol Endocrinol 15:2197-2210.
26. Jerome LA and Papaioannou VE. (2001). DiGeorge syndrome phenotype in mice mutant for the T-box gene, Tbx1. Nat Genet 27:286-291.
27. Kajiyama N, Saito Y, Miyamoto Y, Yoshimura M, Nakayama M, Harada M, Kuwahara K, Kishimoto I, Yasue H, Nakao K. (2000). Lack of association between T-786->C mutation in the 5′-flanking region of the endothelial nitric oxide synthase gene and essential hypertension. Hypertens Res 23:561-565.
28. Kato N, Sugiyama T, Morita H, Nabika T, Kurihara H, Yamori Y, Yazaki Y. (1999). Lack of evidence for association between the endothelial nitric oxide synthase gene and hypertension. Hypertension 33:933-936.
29. Keyt BA, Berleau LT, Nguyen HV, Chen H, Heinsohn H, Vandlen R, Ferrara N. (1996). The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem 271:7788-7795.
30. Keyt BA, Nguyen HV, Berleau LT, Duarte CM, Park J, Chen H, Ferrara N. (1996). Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis. J Biol Chem 271:5638-5646.
31. Khurana VG, Sohni YR, Mangrum WI, McClelland RL, O'Kane DJ, Meyer FB, Meissner I. (2003). Endothelial nitric oxide synthase T-786C single nucleotide polymorphism: a putative genetic marker differentiating small versus large ruptured intracranial aneurysms. Stroke 34:2555-2559.
32. Li B, Fuh G, Meng G, Xin X, Gerritsen ME, Cunningham B, de Vos AM. (2000). Receptor-selective variants of human vascular endothelial growth factor: geeration and characterization. J Biol Chem 275:29823-29828.
33. Liu J, Garcia-Cardena G, Sessa WC. (1996). Palmitoylation of endothelial nitric oxide synthase is necessary for optimal stimulated release of nitric oxide: implications for caveolae localization. Biochemistry 35:13277-13281.
34. Liu J, Hughes TE, Sessa WC. (1997). The first 35 amino acids and fatty acylation sites determine the molecular targeting of endothelial nitric oxide synthase into the Golgi region of cells: a green fluorescent protein study. J Cell Biol 137:1525-1535.
35. Maes C, Carmeliet P, Moermans K, Stockmans I, Smets N, Collen D, Bouillon E, Carmeliet G. (2002). Impaired angiogenesis and endochondral bone formation in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Mech Dev 111:61-73.
36. Mattot V, Moons L, Lupu F, Chernavvsky D, Gomez RA, Collen D, Carmeliet P. (2002). Loss of the VEGF(164) and VEGF(188) isoforms impairs postnatal glomerular angiogenesis and renal arteriogenesis in mice. J Am Soc Nephrol 13:1548-1560.
37. Nakayama M, Yasue H, Yoshimura M, Shimasaki Y, Kugiyama K, Ogawa H, Motoyama T, Saito Y, Ogawa Y, Miyamoto Y, Nakao K. (1999). T-786->C mutation in the 5′-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation 99:2864-2870.
38. Nasreen S, Nabika T, Shibata H., Morivama H, Yamashita K, Masuda J. Kobayashi S. (2002). T-786C polymorphism in endothelial NO synthase gene affects cerebral circulation in smokers: possible gene-environmental interaction. Arterioscler Thromb Vasc Biol 22:605-610.
39. Nielsen HJ, Christensen IJ, Svendsen MN, Hansen U, Werther K, Brunner N, Petersen LJ, Kristensen JK. (2002). Elevated plasma levels of vascular endothelial growth factor and plasminogen activator inhibitor-1 decrease during improvement of psoriasis. Inflamm Res 51:563-567.
40. Oosthuyse B, Moons L, Storkebaum E, Beck H, Nuyens D, Brusselmans K, Van Dorpe J, Hellings P, Gorselink M, Heymans S, Theilmeier G, Dewerchin M, Laudenbach V, Vermylen P, Raat H, Acker T, Vleminckx V, Van Den Bosch L, Cashman N, Fujisawa H, Drost MR, Sciot R, Bruyninckx F, Hicklin DJ, Ince C, Cressens P, Lupu E, Plate KH, Robberecht W, Herbert JM, Collen D, Carmeliet P. (2001). Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 28:131-138.
41. Poltorak Z, Cohen T. Nenfeld G. Gengrinovitch S. (2000). The VEGF splice variants: properties, receptors, and usage for the treatment of ischemic diseases Vascular endothelial growth factor (VEGF) and its receptors. Herz 25:126-129.
42. Raab S, Beck H, Gaumann A, Yuce A, Gerber HP, Plate K, Hammes HP, Ferrara N, Breier G. (2004). Impaired brain angiogenesis and neuronal apoptosis induced by conditional homozygous inactivation of vascular endothelial growth factor. Thromb Haemost 91:595-605.
43. Ray D, Mishra M, Ralph S, Read I, Davies R, Brenchley P. (2004). Association of the VEGF gene with proliferative diabetic retinopathy but riot protein-uria in diabetes. Diabetes 53:861-864.
44. Reaven GM. ( 1988). Banting lecture 1988: role of insulin resistance in human disease. Diabetes 37:1595-1607.
45. Rossi GP, Cesari M, Zanchetta M, Colonna S, Maiolino G, Pedon L, Cavallin M. Maiolino P, Pessina AC. (2003). The T-786C endothelial nitric oxide synthase genotype is a novel risk factor for coronary artery disease in Caucasian patients of the GENICA study. J Am Coll Cardiol 41:930-937.
46. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. (1983). Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983-985.
47. Sharan K, Surrey S, Ballas S, Borowski M, Devoto M, Wang KF, Sandler E, Keller M. (2004). Association of T-786C eNOS gene polymorphism with increased susceptibility to acute chest syndrome in females with sickle cell disease. Br Haematol 124:240-243.
48. Shoji M, Tsutaya S, Saito R, Takamatu H, Yasujima M. (2000). Positive association of endothelial nitric oxide synthase gene polymorphism with hypertension in northern Japan. Life Sci 66:2557-2562.
49. Stalmans I, Lambrechts D, De Smet F, Jansen S, Wang J, Maity S, Kneer P, von der Ohe M, Swillen A, Maes C, Gewillig M, Molin DG, Hellings P, Boetel T, Haardt M, Compernolle V, Dewerchin M, Plaisance S, Vlietinck R, Emanuel B, Gittenberger-de Groot AC, Scambler P, Morrow B, Driscol DA, Moons L, Esguerra CV, Carmeliet G, Behn-Krappa A, Devriendt K, Collen D, Conway SJ, Carmeliet P. (2003). VEGF: a modifier of the del22q11 (DiGeorge) syndrome? Nat Med 9:173-182.
50. Stalmans I, Ng YS, Rohan R, Fruttiger M, Bouche A, Yuce A, Fujisawa H, Hermans B, Shani M, Jansen S, Hicklin D, Anderson DJ, Gardiner T, Hammes HP, Moons L, Dewerchin M, Collen D, Carmeliet P, D'Amore PA. (2002). Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J Clin Invest 109:327-336.
51. Stevens A, Soden J, Brenchley PE, Ralph S, Ray DW. (2003). Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 63:812-816.
52. Tesauro M, Thompson WC, Rogliani P, Qi L, Chaudhary PP, Moss J. (2000). Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298. Proc Natl Acad Sci U S A 97:2832-2835.
53. Ukkola O, Erkkila PH, Savolainen MJ, Kesaniemi YA. (2001). Lack of association between polymorphisms of catalase, copper-zinc superoxide dismutase (SOD), extracellular SOD and endothelial nitric oxide synthase genes and macroangiopathy in patients with type 2 diabetes mellitus. J Intern Med 249:451-459.
54. Via M, Lopez-Alomar A, Valveny N, Gonzalez-Perez E, Bao M, Esteban E, Pinto X, Domingo E, Moral P. (2003). Lack of association between eNOS gene polymorphisms and ischemic heart disease in the Spanish population. Am J Med Genet 116A:243-248.
55. Wang CL, Hsu LA, Ko YS, Ko YL, Lee YH. (2001). Lack of association between the Glu298Asp variant of the endothelial nitric oxide synthase gene and the risk of coronary artery disease among Taiwanese. J Formos Med Assoc 100:736-740.
56. Wang XL, Sim AS, Badenhop RF, McCredie RM, Wilcken DE. (1996). A smokin-dependent risk of coronary artery disease associated with a polymorphism of the endothelial nitric oxide synthase gene. Nat Med 2:41-45.
57. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE. (2000). Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 12:1232-1235.
58. Weston GC, Haviv I, Rogers PA. (2002). Microarray analysis of VEGF-responsive genes in myometrial endothelial cells. Mol Hum Reprod 8:855-863.
59. Whittle C, Gillespie K, Harrison R, Mathieson PW, Harper SJ. (1999). Heterogeneous vascular endothelial growth factor (VEGF) isoform mRNA and receptor mRNA expression in human glomeruli, and the identification of VEGF148 mRNA, a novel truncated splice variant. Clin Sci (Lond) 97:303-312.
60. Xia YP, Li B, Hylton D, Detmar M, Yancopoulos GD, Rudge JS. (2003). Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 102:161-168.
61. Yang S, Toy K, Ingle G, Zlot C, Williams PM, Fuh C, Li B, de Vos A, Gerritsen ME. (2002). Vascular endothelial growth factor-induced genes in human umbilical vein endothelial cells: relative roles of KDR and Flt-1 receptors. Arterioscler Thromb Vasc Biol 22:1797-1803.
62. Yoshimura M, Yasue H, Nakayama M, Shimasaki Y, Ogawa H, Kugiyama K, Saito Y, Miyamoto Y, Ogawa Y, Kaneshige T, Hiramatsu H, Yoshioka T, Kamitani S, Teraoka H, Nakao K. (2000). Genetic risk factors for coronary artery spasm: significance of endothelial nitric oxide synthase gene T-786->C and missense Glu298Asp variants. J Investig Med 48:367-374.
63. Yoshimura T, Yoshimura M, Tabata A, Yasue H, Okamura H. (2001). The missense Glu298Asp variant of the endothelial nitric oxide synthase gene is strongly associated with placental abruption. Hum Genet 108:181-183.
64. Young HS, Summers AM, Bhushan M, Brenchley PE, Griffiths CE. (2004). Single-nucleotide polymorphisms of vascular endothelial growth factor in psoriasis of early onset. J Invest Dermatol 122:209-215.
65. Zanchi A, Moczulski DK, Hanna LS, Wantman M, Warram JH, Krolewski AS. (2000). Risk of advanced diabetic nephropathy in type 1 diabetes is associated with endothelial nitric oxide synthase gene polymorphism. Kidney Int 57:405-413.